SFI (Soho Flordis International) Health, a global premium natural healthcare company headquartered in Sydney, Australia, has mandated Australian boutique corporate advisory firm Saltire Capital Partners to seek acquisition targets, Saltire Partner Peter Gardiner told Mergermarket.
The company is looking to make a series of acquisitions, above all in the cognitive health and human microbiome (probiotics) segments, Saltire Partner Rahavan Yoganathan added. The company is focused on acquisitions in Australia, but would also be interested in targets in Asia, the US and Europe, Yoganathan said.
SFI Health and Saltire are interested in hearing from potential acquisition targets that fit the profile, or their sellside advisors, Gardiner said.
Without disclosing revenue numbers, Gardiner noted that the company employs more than 450 employees worldwide and its products are sold in more than 50 countries.
The company has manufacturing facilities in the US, UK and Switzerland, and offers product development and clinical research services. Its vision is to be the trusted global leader in developing and delivering human microbiome and cognitive natural solutions.
SFI’s previous acquisitions include US-based Prothera, Switzerland-based Ginsana and UK-based Potter’s Herbals. Its other brands are Klaire Labs, Flordis and Equazen.
SFI Health’s Group CFO and Interim Asia-Pacific General Manager, Gilbert Cheong Foo, commented that Saltire is uniquely positioned to advise the company, given that the partners have extensive expertise and connectivity in the health sector and understanding of mid-market businesses.
Saltire Capital Partners was recently established by Gardiner and Yoganathan, with Douglas Farrell as Non-Executive Chairman. Farrell is Managing Partner of Quintet Yorkway, recently formed by the merger of Quintet Partners and Yorkway Partners, and was previously head of M&A and real estate banking at Citigroup in Australia and New Zealand.
by Christel Thunell in Sydney
- Read the Mergermarket article here.